Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 9/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138202 | 0.91 | HDAC3 (0.56) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL25138043 | 0.88 | FGFR1 (0.55) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14091359 | 0.86 | MGLL (0.46) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14115822 | 0.85 | MGLL (0.49) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14115798 | 0.85 | HDAC6 (0.49) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL25138167 | 0.83 | CHEK2 (0.55) | MGLLCHEK2 | |
| SCHEMBL14091381 | 0.82 | CHEK2 (0.46) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14091399 | 0.81 | MGLL (0.46) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14090244 | 0.79 | MGLL (0.50) | MGLLHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14090345 | 0.78 | AMY1A (0.49) | MGLLHDAC6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117938-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES, DISORDERS AND CONDITIONS INVOLVING TRINUCLEOTIDE REPEATS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117938-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES, DISORDERS AND CONDITIONS INVOLVING TRINUCLEOTIDE REPEATS | SMN1; SMN2, TRDMT1, HNRNPA2B1 | MGLL 4466/4885HDAC6 590/4885HDAC3 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.